Author - Melane Sampson

Developments

DarioHealth glucose monitor in pact for pharma clinical study

DarioHealth (NASDAQ:DRIO) has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing diabetes that will use DarioHealth to run and track blood glucose...

February 8, 2018

Markets

Ladenburg starts Zynerba Pharma at buy; PT $25.50

Ladenburg Thalmann initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $25.50 price target. The stock closed at $12.07 on Jan. 26. Zynerba is developing two clinical-stage synthetic...

January 29, 2018

Markets

Maxim vaults BeiGene price target to $120

Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced...

September 28, 2017

Author - Melane Sampson

DarioHealth glucose monitor in pact for pharma clinical study

Ladenburg starts Zynerba Pharma at buy; PT $25.50

Maxim vaults BeiGene price target to $120

Subscribe